Prelude Capital Management, LLC Contrafect Corp Transaction History

Prelude Capital Management, LLC

  • $1.39 Billion
  • Q2 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
SELL
$2.79 - $4.45 $96,813 - $154,415
-34,700 Closed
0 $0
Q1 2021

May 17, 2021
BUY
$4.46 - $6.68 $92,322 - $138,276
20,700 Added 147.86%
34,700 $167,000
Q3 2020

Nov 16, 2020
BUY
$5.05 - $6.99 $6,883 - $9,527
1,363 Added 10.79%
14,000 $74,000
Q2 2020

Aug 14, 2020
BUY
$4.69 - $7.81 $59,267 - $98,694
12,637 New
12,637 $81,000

Others Institutions Holding CFRX

# of Institutions
2
Shares Held
49.2K
Call Options Held
0
Put Options Held
0
View Full List

About CONTRAFECT Corp

CFRX Quotes by TradingView
  • Ticker CFRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,332,700
  • Market Cap $1.18M
  • Description
  • ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...
More about CFRX
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email